HematologyNews.net

Hematology Xagena

Search results for "Carfilzomib"

Results from a study published in Blood, the Journal of the American Society of Hematology ( ASH ), have demonstrated that inclusion of Carfilzomib ( Kyprolis ), a novel targeted therapy for multiple ...


The Food and Drug Administration ( FDA ) has granted accelerated approval of Kyprolis ( Carfilzomib ) for injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myelo ...


The medical journal Leukemia has published results from the Phase 2 trial known as PX-171-005, an open-label, multicenter clinical trial evaluating Kyprolis ( Carfilzomib ) for injection in patients w ...


Carfilzomib ( Kyprolis ) is a selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In an open-label, single-arm phase 2 study ( PX-171-003- ...


In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment of multiple myeloma were presented. Alternating vs sequential regimens I ...


A planned interim analysis has shown that the phase 3 head-to-head clinical trial ENDEAVOR evaluating Carfilzomib ( Kyprolis ) for injection in combination with low-dose Dexamethasone versus Bortezomi ...


Data from a secondary analysis of the pivotal phase 3 ASPIRE trial that showed Carfilzomib ( Kyprolis ) for injection in combination with Lenalidomide ( Revlimid ) and Dexamethasone ( KRd) improved pr ...


Immunotherapy in multiple myeloma is emerging as an effective modality in therapy of multiple myeloma with the approval of several monoclonal antibodies and encouraging results for vaccines and T cell ...


Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were presented. The study met the key secondary endpoint of overall survival, demons ...